Abstract
In The Lancet Oncology, Patrick Y Wen and colleagues present interim results from the Rare Oncology Agnostic Research (ROAR) study, 1 Wen PY Stein A van den Bent M et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2021; (published online Nov 24.)https://doi.org/10.1016/S1470-2045(21)00578-7 Summary Full Text Full Text PDF Scopus (8) Google Scholar an ongoing phase 2, open-label, single-arm, multicentre basket trial of targeted therapies in BRAF-mutant cancers, showing positive results for dabrafenib plus trametinib in patients with high-grade glioma and low-grade glioma. Long challenged with targeted therapeutics, the neuro-oncology community can now see the possible use of combinatorial therapeutics for BRAFV600E-mutant glioma. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialDabrafenib plus trametinib showed clinically meaningful activity in patients with BRAFV600E mutation-positive recurrent or refractory high-grade glioma and low-grade glioma, with a safety profile consistent with that in other indications. BRAFV600E testing could potentially be adopted in clinical practice for patients with glioma. Full-Text PDF
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
